Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepping-down Approach vs MDI in Poorly-controlled Diabetes
NCT02846233Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin, albiglutide and dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Hemoglobin A1c at 16 weeks. Started Aug 2016; status: completed.
02
Drugs
empagliflozinalbiglutidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02846233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846233.